Interní Med. 2002; 4(1): 10-14
Erektilní dysfunkce u stárnoucích mužů
- MUDr. Karel Kočí CSc
- Privátní andrologická ordinace Andromeda
Keywords: erectile dysfunction, pharmacotherapy, sildenafil, intracavernous injection, vacuum assistive devices, operation.
Published: December 31, 2002 Show citation
Kočí K. Erektilní dysfunkce u stárnoucích mužů. Interní Med. 2002;4(1):10-14.
Erektilní dysfunkce (ED) je neschopnost dosáhnout a udržet erekci dostatečnou pro uspokojivý pohlavní styk. Prevalence ED je relativně vysoká - více než polovina mužů mezi 40-70 lety trpí nějakou formou ED. Plná čtvrtina mužů v tomto věkovém rozmezí má středně závažnou dysfunkci a každý desátý muž je postižen úplnou ztrátou erekce. Naprostá většina pacientů by uvítala, kdyby dialog o jejich sexuálním životě inicioval lékař.
Etiologie ED je v cca 20 % případů psychogenní (nedostatek sebedůvěry, obava ze selhání, problémy ve vztahu k partnerce, deprese apod.), zbývajících 80 % případů ED má příčinu organickou. Nejčastěji jde o vaskulogenní poruchu při ateroskleróze.
Metody léčby ED mohou být konzervativní nebo invazivní. Do první skupiny patří psychoterapie, perorální farmakoterapie a aplikace podtlakových erektorů. Miniinvazivní metodou je intrakavernózní aplikace vazoaktivních látek, nejčastěji alprostadilu. Do invazivních postupů spadají cévní operace na arteriálním nebo venózním řečišti penisu a implantace penilních endoprotéz. Současné léčebné metody umožňují efektivní a bezpečnou léčbu téměř ve všech případech ED.
Erectile Dysfunction in Aging Men
Erectile dysfunction (ED) is an inability to reach and sustain erection sufficient for a satisfactory sexual intercourse. Prevalence of ED is relatively high - more than one half of men among 40-70 years suffer from some form of ED. A good one forth of men in this range of age experiences a moderate to severe dysfunction, every tenth man copes with a total loss of erection. The majority of patients would welcome a dialogue about their sexual life being initiated by a physician.
Etiology of ED stems in about 20% from psychological causes (lack of self-esteem, fear of failure, problems in an partner´s relationship, depression and so on), an organic cause can be found in the rest of 80% of ED cases. The vascular impairment due to atherosclerosis is the major culprit. Treatment modalities of ED could be conservative or invasive. The former is represented by psychotherapy, medical therapy and aplication of vacuum assistive devices. Mini-invasive method uses intracavernous aplication of vasoactive drugs, most frequently alprostadil. Vessel operations on arterial or venous beds of penis and implantations of penile implants are ranked among invasive procedures. Up to date therapeutical methods enable an effective and safe solution nearly of all cases of ED.
Download citation
References
- Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995; 22: 699-709.
Go to original source...
Go to PubMed...
- Bukofzer S, Livesey N. Safety and tolerability of apomorphine SL (Uprima(R)). Int J Impot Res 2001; 13 (suppl. 3): 40-44.
Go to original source...
Go to PubMed...
- Dula E, Bukofzer S, Perdok R, et al.: Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558-564.
Go to original source...
Go to PubMed...
- Feldman R, Meuleman EJH, Steers W. Sildenafil (ViagraTM) in the treatment of erectile dysfunction: analysis of two flexible dose-escalation studies. Int J Impot Res 1998; 10 (suppl 3) 33.
- Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. A Engl J Med 1998; 338: 1397-1404.
Go to original source...
Go to PubMed...
- Hellstrom WJG. Advances in male sexual dysfunction. Andrology in the 21st century. Proceedings of the VIIth International Congress of Andrology, Montréal, June 15.-19. 2001: 533-542.
- Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol 1999; 84: 11N-17N.
Go to original source...
Go to PubMed...
- McCullough AR, Siegel RL, Shpilsky AB. Intercourse success rates with sildenafil citrate. J Urol 1999; 165, 5: 170.
- Michal V, Kramar R, Pospichal J. Femoropudendal bypass, internal iliac thrombendarterectomy and direct arterial anastomosis to the cavernous body in the treatment of erectile impotence. Bull Soc Int Chir 1974; 33: 341-345.
- Padma-Nathan H. A 24-week, fixed-dose study to asses the efficacy and safety of sildenafil (ViagraTM) in men with erectile dysfunction. J Urol. 1998; 159 (suppl): 238.
Go to PubMed...
- Padma-Nathan H, Steers WD, Wicker PA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract 1998; 52: 375-379.
Go to original source...
Go to PubMed...
- Pritzker MR. The penile stress test: a window to the heart of man? American Heart Association Annual Meeting, 10. 11. 1999, Atlanta, Georgia.
- Sairam K. Screening for diabetes. What are we really doing? Br J Urol Int 2001; 88: 68-71.
Go to original source...
Go to PubMed...
- Vardi Y, Bulus M, Reisner S, et al. Ergometric studies for evaluating sildenafil effect in cardiac patients. 94th Annual Meeting AUA, May 2, 2000, Atlanta.